HomeBUSINESS
BUSINESS

EA Pharma Licenses SHPT Treatment to China Firm
(Jun.13.2018)

EA Pharma, a gastroenterology subsidiary of Eisai, said on June 12 that it is granting Tianjin-based Tasly Pharmaceutical Group exclusive rights to develop and market its secondary hyperparathyroidism (SHPT) treatment AJT240 in China including Hong Kong and Macau. The financial terms of the deal were undisclosed ...
(LOG IN FOR FULL STORY)